How expensive can drugs be? The pharmaceutical industry is under increasing pressure to justify it, given the cost of over 100,000 Swiss francs for combined cancer treatments.
Drug prices set it Federal Public Health Office (BAG). The broadcast "Rundschau" by the SRF on Wednesday uses an example to show how the negotiations are taking place. According to the documents that the SSP published under public law, they arrived Roche the much higher cost of medicines from the Federal Office was initially required.
The drug package Perjeta should cost 1850 francs to enter the market in 2013, according to the federal government. Rosh set a price of 3450 francs. In "Rundschau" it was reportedly that BAG was under pressure to fix the price for Roche's cancer medicine. Spokesman Thomas Christen in the show said BAG was under pressure from the industry. The federal office is in 60 cases in court, because there is no agreed price.
However, in the case of Perjeta, BAG is opposed to the allegations. "The fact is that the prices for Perjeta are successful," says Kristen this newspaper. Thus, the drug in combination therapy is cheaper than the effectively paid prices abroad.
The Federal Council ripples
The NGO Public Eye uses the program as an opportunity to confirm its claim that the Confederation must obtain a mandatory Perjeta license. In a compulsory license, the pharmaceutical company is forced to have one of its active ingredients manufactured by a third party for compensation, in order to reduce the price and thereby ensure the supply of the population.
SP State Advisor Angelo Barile filed a similar law in June. The Federal Council does not want to know about it. "Facilitating healthcare costs through mandatory licenses for new, expensive drugs is in terms of the Federal Council in the current patent and the law on drugs is not possible," his statement said. Thus, even the holder of a compulsory license to authorize a self-produced drug "collects all clinical data independently and submits it to the regulatory authority, which lasts for several years and is expensive."
The federal government should keep prices low through threats
Public opinion wants to refute this argument with a report by Professor Valerie Yunode of the University of Geneva. Thus, the owner of the compulsory license may request the necessary information on Roche authorization if the patent court has established a "public interest" in a compulsory license. Otherwise, Roche could violate the antitrust laws because he used his dominant position.
Drug experts find it illusory that the government, through a mandatory license, risks being responsible for drug production. According to the "Public Eye", the campaign is primarily concerned that the Federal Council should threaten means of compulsory licensing in order to reduce the prices of the pharmaceutical industry.
Created: January 30, 2019, 20:28 clock